Georgia vs New Jersey on USAspending: $9.7B vs $8.1B

Georgia’s $9.7B versus New Jersey’s $8.1B

These figures are USAspending.gov obligations, not Treasury outlays. Georgia’s $9.7B is about 1.2 times New Jersey’s $8.1B. The comparison scores place of performance in the award file. Georgia holds the larger all-years total, and that stock lines up with a larger population of 11,180,878 against 9,500,851.

Award counts run the other way, and the gap is extreme. New Jersey has 1,162,765 awards; Georgia has 278,028. New Jersey’s file is busier in rows and lighter in dollars. Georgia’s file is heavier in dollars on far fewer actions — a higher typical booking. The $9.7B versus $8.1B ranking is a dollar ranking, not a row ranking.

Nearly matched per capita: $95.66 versus $92.49

Georgia’s 11,180,878 residents exceed New Jersey’s 9,500,851. After dividing the obligation stocks by those Census counts, Georgia shows $95.66 per capita and New Jersey shows $92.49. Intensity is close even though Georgia’s $9.7B stock exceeds New Jersey’s $8.1B. This pair is not a high-versus-low intensity contest.

A $95.66 per-person reading in Georgia on 11,180,878 residents is an intensity fact attached to $9.7B. New Jersey’s $92.49 on 9,500,851 residents is attached to $8.1B. This table scores USAspending place of performance, not GDP. Similar intensity can still sit on very different row counts.

Aircraft in Georgia, pharmaceuticals in New Jersey

Georgia’s top industry is aircraft manufacturing. New Jersey’s is pharmaceutical preparation manufacturing. Those labels mark the largest NAICS slice in each state’s file, not a full industrial census. Aircraft awards and drug-manufacturing awards are different lead products sitting on $9.7B and $8.1B.

An aircraft-manufacturing lead can concentrate large production awards inside Georgia’s 278,028-award file. A pharmaceutical-preparation lead inside New Jersey’s 1,162,765-award file can sit among many smaller actions. Mix and scale both differ. Neither industry name explains every dollar.

FY2026: $1.1B in Georgia vs $878.7M in New Jersey

FY2026 obligations are $1.1B in Georgia and $878.7M in New Jersey. Georgia’s latest year remains ahead, matching the direction of the $9.7B versus $8.1B stacked ranking. Recency questions belong in FY2026. The stacked totals remain the full USAspending.gov aggregate this comparison uses. Both years are obligations, not outlays.

Do not divide those FY figures by Georgia’s 278,028 or New Jersey’s 1,162,765 all-years awards. Per capita of $95.66 on 11,180,878 residents versus $92.49 on 9,500,851 residents is the intensity comparison. Both cuts are USAspending.gov obligations.

Similar intensity, inverted row count

Georgia leads stacked dollars ($9.7B vs $8.1B), population (11,180,878 vs 9,500,851), per capita ($95.66 vs $92.49), and FY2026 ($1.1B vs $878.7M). New Jersey leads award count (1,162,765 vs 278,028). That row inversion — many more New Jersey actions on a smaller dollar stock — is the distinctive fact in this pair.

Aircraft manufacturing versus pharmaceutical preparation manufacturing is mix inside files that contain many other industries. Use the Georgia and New Jersey hubs for agencies and recipients. Keep $9.7B and $8.1B labeled as obligations.

How to use the Georgia and New Jersey hubs

New Jersey’s 1,162,765 awards on $8.1B versus Georgia’s 278,028 awards on $9.7B is the row inversion. Per capita of $92.49 versus $95.66 is nearly matched on 9,500,851 and 11,180,878 residents. Open the Georgia hub and the New Jersey hub for agencies and recipients. Aircraft manufacturing versus pharmaceutical preparation manufacturing is mix, not a census of either stock.

FY2026’s $1.1B versus $878.7M follows Georgia’s stacked lead. These are USAspending.gov obligations, not Treasury outlays. Do not divide latest-year dollars by all-years award counts. Place of performance can differ from the paying agency’s location. Use the hubs when the next question is recipients. Keep $9.7B and $8.1B labeled as obligations so similar intensity is not mistaken for similar row counts.

Georgia versus New Jersey is similar intensity of $95.66 versus $92.49 on $9.7B versus $8.1B with inverted rows: 278,028 awards versus 1,162,765. Aircraft manufacturing and pharmaceutical preparation manufacturing are lead slices. FY2026 of $1.1B versus $878.7M follows Georgia. Census counts are 11,180,878 and 9,500,851. Obligations are not outlays. The Georgia and New Jersey hubs hold agencies and recipients. New Jersey’s 1,162,765 awards on $8.1B versus Georgia’s 278,028 awards on $9.7B is the row inversion. Per capita of $92.49 versus $95.66 on 9,500,851 and 11,180,878 residents is close. FY2026’s $878.7M versus $1.1B follows Georgia. Pharmaceuticals versus aircraft is mix.

Questions

Which state has more federal spending, Georgia or New Jersey?

Georgia leads in USAspending.gov obligations: $9.7B versus New Jersey’s $8.1B. New Jersey has far more awards (1,162,765 vs 278,028). Populations are 11,180,878 in Georgia and 9,500,851 in New Jersey. Spending per capita is $95.66 in Georgia and $92.49 in New Jersey. FY2026 obligations are $1.1B and $878.7M. These are obligations, not Treasury outlays.

Why does New Jersey have more federal awards than Georgia but fewer dollars?

New Jersey logs 1,162,765 awards on $8.1B. Georgia logs 278,028 awards on $9.7B. New Jersey’s file is busier in rows and lighter in dollars, which implies a smaller typical booking. Per capita is close ($92.49 vs $95.66). Populations are 9,500,851 and 11,180,878. FY2026 favors Georgia ($1.1B vs $878.7M).

What industries lead Georgia and New Jersey federal awards?

Georgia’s top industry is aircraft manufacturing. New Jersey’s is pharmaceutical preparation manufacturing. Those slices sit on $9.7B and $8.1B in obligations. They mark the largest grouping in each file, not every award in either state. Award counts are 278,028 in Georgia and 1,162,765 in New Jersey.

Are Georgia vs New Jersey figures Treasury outlays?

No. SpendingVault uses USAspending.gov obligations. Outlays are cash payments and can lag. The $9.7B and $8.1B stacked totals and FY2026 amounts of $1.1B and $878.7M measure award commitments by place of performance, not Monthly Treasury Statement payments. Place of performance can differ from where the paying agency sits.